JP7710446B2 - ヒトil‐13に結合特異性を有する抗体 - Google Patents

ヒトil‐13に結合特異性を有する抗体

Info

Publication number
JP7710446B2
JP7710446B2 JP2022534780A JP2022534780A JP7710446B2 JP 7710446 B2 JP7710446 B2 JP 7710446B2 JP 2022534780 A JP2022534780 A JP 2022534780A JP 2022534780 A JP2022534780 A JP 2022534780A JP 7710446 B2 JP7710446 B2 JP 7710446B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
antibodies
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507282A5 (cg-RX-API-DMAC10.html
JP2023507282A (ja
Inventor
ジョン ライトウッド、ダニエル
アダムズ、ラルフ
トーマス パルフラマン、ロジャー
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2023507282A publication Critical patent/JP2023507282A/ja
Publication of JP2023507282A5 publication Critical patent/JP2023507282A5/ja
Application granted granted Critical
Publication of JP7710446B2 publication Critical patent/JP7710446B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022534780A 2019-12-20 2020-12-18 ヒトil‐13に結合特異性を有する抗体 Active JP7710446B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1919062.8 2019-12-20
GBGB1919062.8A GB201919062D0 (en) 2019-12-20 2019-12-20 Antibody
PCT/EP2020/087053 WO2021123190A1 (en) 2019-12-20 2020-12-18 Antibody with binding specificity for human il-13.

Publications (3)

Publication Number Publication Date
JP2023507282A JP2023507282A (ja) 2023-02-22
JP2023507282A5 JP2023507282A5 (cg-RX-API-DMAC10.html) 2023-12-14
JP7710446B2 true JP7710446B2 (ja) 2025-07-18

Family

ID=69322674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534780A Active JP7710446B2 (ja) 2019-12-20 2020-12-18 ヒトil‐13に結合特異性を有する抗体

Country Status (14)

Country Link
US (1) US12637507B2 (cg-RX-API-DMAC10.html)
EP (1) EP4077382A1 (cg-RX-API-DMAC10.html)
JP (1) JP7710446B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220117305A (cg-RX-API-DMAC10.html)
CN (1) CN114829398B (cg-RX-API-DMAC10.html)
AU (1) AU2020406155A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022011619A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164231A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022001684A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022008268A2 (cg-RX-API-DMAC10.html)
GB (1) GB201919062D0 (cg-RX-API-DMAC10.html)
IL (1) IL293812A (cg-RX-API-DMAC10.html)
MX (1) MX2022007117A (cg-RX-API-DMAC10.html)
WO (1) WO2021123190A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523154A (ja) 2006-01-11 2009-06-18 グラクソ グループ リミテッド キメラおよびヒト化抗ヒトil−13抗体
JP2011225574A (ja) 2004-06-17 2011-11-10 Wyeth Llc Il−13結合剤
JP2012506695A (ja) 2008-08-20 2012-03-22 ヤンセン バイオテツク,インコーポレーテツド 改変された抗il−13抗体、組成物、方法、及び使用
JP2012520067A (ja) 2009-03-11 2012-09-06 ユセベ ファルマ ソシエテ アノニム ヒトil−13に結合特異性を有する抗体分子
JP2015037401A (ja) 2004-06-09 2015-02-26 ワイス・エルエルシー ヒトインターロイキン−13に対する抗体およびそれらの使用
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE19653722C2 (de) 1996-12-10 2000-06-29 Brose Fahrzeugteile Beidseitig wirkende Verstellvorrichtung
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
EP1049787B1 (en) 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
GB201522394D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2018018031A1 (en) * 2016-07-22 2018-01-25 New York University Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
TWI787203B (zh) 2016-09-23 2022-12-21 美商建南德克公司 Il-13拮抗劑用於治療異位性皮炎之用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015037401A (ja) 2004-06-09 2015-02-26 ワイス・エルエルシー ヒトインターロイキン−13に対する抗体およびそれらの使用
JP2011225574A (ja) 2004-06-17 2011-11-10 Wyeth Llc Il−13結合剤
JP2009523154A (ja) 2006-01-11 2009-06-18 グラクソ グループ リミテッド キメラおよびヒト化抗ヒトil−13抗体
JP2012506695A (ja) 2008-08-20 2012-03-22 ヤンセン バイオテツク,インコーポレーテツド 改変された抗il−13抗体、組成物、方法、及び使用
JP2012520067A (ja) 2009-03-11 2012-09-06 ユセベ ファルマ ソシエテ アノニム ヒトil−13に結合特異性を有する抗体分子
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Mol. Biol.,2017年,Vol.429,pp.208-219

Also Published As

Publication number Publication date
CN114829398A (zh) 2022-07-29
AU2020406155A1 (en) 2022-08-04
BR112022011619A2 (pt) 2022-12-20
CA3164231A1 (en) 2021-06-24
MX2022007117A (es) 2022-07-11
IL293812A (en) 2022-08-01
US12637507B2 (en) 2026-05-26
CL2022001684A1 (es) 2023-05-26
EP4077382A1 (en) 2022-10-26
CN114829398B (zh) 2025-05-27
CO2022008268A2 (es) 2022-06-21
US20230084464A1 (en) 2023-03-16
KR20220117305A (ko) 2022-08-23
WO2021123190A1 (en) 2021-06-24
JP2023507282A (ja) 2023-02-22
GB201919062D0 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
JP7161400B2 (ja) Cd22に結合する抗体分子
RU2743590C2 (ru) Молекулы со специфичностью в отношении cd79 и cd22
US8993731B2 (en) PD-1 antibody
JP6998857B2 (ja) Cd79に結合する抗体分子
CN104321341A (zh) 序列对称性的修饰的IgG4双特异性抗体
CN105026431A (zh) 单接头FabFv抗体和制备其的方法
JP7689125B2 (ja) ヒトil-13及びil-17に対する結合特異性を有する多重特異性抗体
CN114829398B (zh) 对人il-13具有结合特异性的抗体
US11091542B2 (en) Antibody molecules which bind TNF alpha
RU2827946C1 (ru) Мультиспецифическое антитело со специфичностью связывания il-13 и il-17 человека
HK40069079A (en) Antibody with binding specificity for human il-13.
HK40069078A (en) Multi-specific antibody with binding specificity for human il-13 and il-17

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250708

R150 Certificate of patent or registration of utility model

Ref document number: 7710446

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150